Last updated: 11/07/2018 19:22:22
A Multi-centre, Randomised, Parallel-Group, Double-Blind Study Comparing Inhaled GR33343G 50mcg and 100mcg Twice Daily for 3 Months in Patients With Moderate to Severe Reversible Airways Obstruction
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multi-centre, Randomised, Parallel-Group, Double-Blind Study Comparing Inhaled GR33343G 50mcg and 100mcg Twice Daily for 3 Months in Patients With Moderate to Severe Reversible Airways Obstruction
Trial description: A Multi-centre, Randomised, Parallel-Group, Double-Blind Study Comparing Inhaled GR33343G 50mcg and 100mcg Twice Daily for 3 Months in Patients With Moderate to Severe Reversible Airways Obstruction
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Palmer JBD, Stuart AM, Shepherd GL, Viskum K. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease – a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100mcg) with salmeterol (50mcg). Respir Med 1992; 86 (5): 409-417
Medical condition
Airway Obstruction
Product
salmeterol
Collaborators
Not applicable
Study date(s)
November 1988 to October 1989
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1989-02-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website